# US 2026/0293956 A1 · Nutritional composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0293956 A1
- Document ID: US20260293956A1
- Status: Published application
- Kind: A1
- Application number: 19/477,424
- Filed: 2024-04-26
- Published: 2026-10-01
- Earliest claimed: 2023-04-28
- Assignees: Societe des Produits Nestle S.A.
- Applicants: SociéTé Des Produits Nestlé S.A.
- Inventors: Kieran JAMES; Norbert SPRENGER; Peter ERDMANN; Florac DE BRUYN; Hanne Lore Paula TYTGAT
- Web page: https://patentgrep.com/patent/US20260293956A1

## CPC

- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/18: Peptides; Protein hydrolysates
- A23L 33/19: Dairy proteins
- A23L 33/21: Addition of substantially indigestible substances, e.g. dietary fibres
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

The present invention provides a combination comprising or consisting of lacto-N-fucopentaose-1 (LNFP-I), a LNFP-1 metabolizing Bifidobacterium, for example Bifidobacterium longum subsp. infantis and a galactose source, or a nutritional composition comprising lacto-N-fucopentaose-1 (LNFP-I), aa LNFP-1 metabolizing Bifidobacterium, for example Bifidobacterium longum subsp. infantis and a galactose source, wherein the galactose source consists of a structure of Formula (I): Hex1(n)-Hex2(m) (Formula I) wherein: Hex1 is galactose, Hex2 is galactose or glucose, n=1-9, and m=1.

## Claims

### Claim at position 1

1: A nutritional composition comprising lacto-N-fucopentaose-I (LNFP-I), a LNFP-1 metabolizing Bifidobacterium, and a galactose source, wherein the galactose source consists of a structure of Formula I:
wherein:
Hex1 is galactose,
Hex2 is galactose or glucose,
n
=
1
-
9
,
and
m
=
1.

### Claim at position 2 (depends on 1)

2: The nutritional composition according to claim 1, wherein the LNFP-1 metabolizing Bifidobacterium is selected from the group consisting of: Bifidobacterium lactis, B. longum, Bifidobacterium breve, B. longum subsp. infantis, B. longum subsp. iuvenis, B. bifidum, B. pseudocatenulatum, B. kashiwanohense, and any combination thereof.

### Claim at position 3 (depends on 1)

3: The nutritional composition according to claim 1, wherein the LNFP-1 metabolizing Bifidobacterium is Bifidobacterium longum subsp. infantis.

### Claim at position 4 (depends on 1)

4: The nutritional composition according to claim 1, wherein the galactose source is selected from the group consisting of galacto-oligosaccharides (GOS), Bovine Milk-derived Oligosaccharides (BMOS) and combinations thereof.

### Claim at position 5 (depends on 1)

5: The nutritional composition according to claim 1, wherein the nutritional composition further comprises a protein source.

### Claim at position 6 (depends on 5)

6: The nutritional composition according to claim 5, wherein the protein source comprises at least one component selected from the group consisting of
a) skimmed milk and demineralized, casein glycomacropeptide (CGMP)-reduced sweet whey;
b) skimmed milk and CGMP-free acid or native whey;
c) CGMP-free whey protein isolate and sweet whey protein concentrate;
d) demineralized CGMP-reduced sweet whey and demineralized sweet whey;
e) skimmed milk and alpha-lactalbumin-enriched whey protein; and
f) a mixture thereof.

### Claim at position 7 (depends on 5)

7: The nutritional composition according to claim 5, wherein the protein source comprises:
a) skimmed milk and demineralized, casein glycomacropeptide (CGMP)-reduced sweet whey;
b) CGMP-free whey protein isolate and sweet whey protein concentrate; or
c) demineralized CGMP-reduced sweet whey and demineralized sweet whey.

### Claim at position 8 (depends on 5)

8: The nutritional composition according to claim 5, wherein the protein source is partially hydrolysed CGMP-free whey protein isolate and sweet whey protein concentrate.

### Claim at position 9 (depends on 5)

9: The nutritional composition according to claim 5, wherein the protein source is partially hydrolysed demineralized CGMP-reduced sweet whey and demineralized sweet whey.

### Claim at position 10 (depends on 1)

10: The nutritional composition according to claim 1 any one of the preceding claims, wherein the LNFP-I is present in a total amount from 25 mg/L to 5000 mg/L of the nutritional composition or 0.02-3.75 g/100 g of the nutritional composition.

### Claim at position 11 (depends on 1)

11: The nutritional composition according to claim 1, wherein the nutritional composition is an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, an infant cereal composition, a growing-up milk, a fortifier or a supplement.

### Claim at position 12 (depends on 1)

12: A method of increasing levels of indole-3-lactic acid (ILA) in the gastrointestinal tract of a subject, the method comprising administering the nutritional composition of claim 1 to the subject.

### Claim at position 13 (depends on 1)

13: A method of modulating the microbiota of a subject, the method comprising administering the nutritional composition of claim 1 to the subject.

### Claim at position 14 (depends on 13)

14: The method according to claim 13, wherein the modulating the microbiota of the subject comprises increasing the abundance of the LNFP-1 metabolizing Bifidobacteria in the gastrointestinal tract of the subject.

### Claim at position 15 (depends on 13)

15: The method according to claim 13, wherein the subject is an infant, a young child or a child.

### Claim at position 16 (depends on 1)

16: A method for:
i) preventing and/or treating viral and/or bacterial infections in a subject;
ii) preventing and/or treating necrotizing enterocolitis (NEC) in a subject;
iii) preventing and/or reducing inflammation in the intestine of a subject;
iv) promoting a healthy immune system in a subject; and/or
v) modulating microbiota of a subject,
the method comprising administering the nutritional composition of claim 1 to the subject.

### Claim at position 17 (depends on 16)

17: The method according to claim 16, wherein the nutritional composition is administered in an amount effective for increasing levels of ILA in the gastrointestinal tract of the subject.

### Claim at position 18 (depends on 16)

18: The method according to claim 16, wherein the modulating the microbiota of subject comprises increasing an abundance of the LNFP-1 metabolizing Bifidobacteria in the gastrointestinal tract of the subject.

### Claim at position 19 (depends on 16)

19: The method according to claim 16, wherein the subject is an infant, a young child or a child.

### Claim 20

(canceled)

### Claim at position 21 (depends on 12)

21: The method according to claim 12, wherein the LNFP-1 metabolizing Bifidobacterium is Bifidobacterium longum subsp. infantis.
